| Wissenschaftl. Titel | A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy |
| Erkrankung |
Blut:
Akute myeloische Leukämie (AML):
weitere
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 20.08.2024 Admin02
geändert 27.08.2024 Admin07